Patent · US Active

Muteins of tear lipocalin and methods for obtaining the same

US10046027B2 · kind B2 · utility

5Cited by

2References

14Claims

0Family size

Assignee

Pieris Pharmaceuticals GmbH · DE

Inventors

Kristian Jensen · Munich, DE
Martin Huelsmeyer · Freising, DE
Steffen Schlehuber · Ruppertsberg, DE
Andreas Hohlbaum · Paunzhausen, DE
Arne Skerra · Freising, DE
Eric Boudreau · Saint-Lambert-de-Lauzon, CA
Richard E. Jones · Palo Alto, US
Ian Kimber · Grafton, GB
Rebecca Dearman · Grafton, GB

Key dates

Filing date	Dec 28, 2015
Grant date	Aug 14, 2018
Priority date	—
Expiry date	Apr 19, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70521
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.